The global patient registry software market is expected to reach USD 1,429.1 Million by 2022 from USD 807.4 Million in 2017, at a CAGR of 12.1%. Growth in this market is mainly driven by factors such as government initiatives to build patient registries, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and growing use of patient registry data for post-marketing surveillance. With the rapidly growing geriatric population and increasing prevalence of chronic diseases, the necessity of population health management has increased. This draws attention towards registry tools. The high adoption of information technology across the globe also supports the growth of this market

Partnerships, collaborations, contracts, agreements, and acquisitions accounted for the majority of the growth strategies adopted by players to sustain their growth in the market.

The patient registry software market is fragmented with several big and small players. Players offer several products across different subsegments of this market. Key players in this market include Phytel, Inc. (US), QUINTILES IMS HOLDINGS, INC. (US), Liaison Technologies. (US), ImageTrend, Inc. (US), FIGmd, Inc. (US), McKesson Corporation (US), CECity.com Inc. (a Premier, Inc. Company) (US), Dacima Software Inc. (US), Global Vision Technologies, Inc. (US), ifa systems AG, (Germany), INC RESEARCH HOLDINGS, INC. (US), M2S (A Medstreaming Company) (US), Optum, Inc (A part of UnitedHealth Group Incorporated) (US), EVADO Pty. Ltd. (Australia), and Velos, Inc. (US).

In 2017, Phytel, Inc. is among the leading players in the patient registry software market. The company mainly focuses on providing population health management solutions to government organizations; TPAs; pharmaceutical, biotechnology, and medical device companies; hospitals; and research centers. The company has a wide geographical presence across the Americas, Europe, the Middle East, Africa, and Asia Pacific. In order to maintain its position in the market, the company adopts various organic as well as inorganic strategies. For instance, in 2016, Phytel agreed with Cleveland Clinic (US) to establish a model for a health system transition to value-based care and population health. Such developments helped the company to enhance its presence in the patient registry software market.

QUINTILES IMS HOLDINGS, INC. has maintained its position in the market by offering high-quality registry solutions. The company has a wide R&D platform with data spanning 298,000+ clinical investigators, 487 indications, and 18 therapeutic areas. In addition, a highly skilled workforce in the company with approximately 900+ clinical educators, 1,100+ medical doctors, and 1,050 PhDs 1,200+ experts in healthcare informatics gives the company a competitive edge. QUINTILES also focuses on partnerships, acquisitions, and expansions to maintain its position in the market. In 2016, IMS and Quintiles merged to create a global leader in healthcare intelligence.

Related Reports:

Patient Registry Software Market by Registry Type (Drugs, Diabetes, Cancer, Asthma, Orthopedic), Software (Integrated, Standalone), Delivery (On premise, Cloud), Functionality (PHM, HIE, POC), Database (Commercial, Public), End User - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com